Richard D. Kim, Antoine Hollebecque, Kristin Ryan, Alison M. Schram. "A phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with
                    <i>FGFR2</i>
                    fusion or rearrangement.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps4251